AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01982448
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00823849
Drug: Cilostazol
RxNorm normalized name: Cilostazol
DrugBank: Cilostazol (DB01166)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: From 50mg, Bid, PO after breakfast and dinner. After 1-week of administration, if no significant study drug related discomfort, the dose can increase to 100mg, Bid, PO. Otherwise, remain at the 50 mg level.
Trial: NCT00823849
Drug: Probucol
RxNorm normalized name: Probucol
DrugBank: Probucol (DB01599)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 250 mg Bid, PO after breakfast and dinner.
Trial: NCT00823849
Drug: Cilostazol+Probucol
RxNorm normalized name: Probucol
DrugBank: Cilostazol (DB01166)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT05442463
Drug: Captopril Tablets
RxNorm normalized name: Captopril Tablets
DrugBank: Captopril (DB01197)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Captorpril challenge to each participant
Trial: NCT02318303
Drug: GSP 301-1 NS (QD)
RxNorm normalized name: NS-2
DrugBank: Reproxalap (DB16688)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSP 301-1 NS (665 μg olopatadine hydrochloride/50 μg mometasone furoate) administered as 2 sprays/nostril
Trial: NCT05442463
Drug: Iohexol
RxNorm normalized name: Iohexol
DrugBank: Iohexol (DB01362)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Iohexol infusion to evaluate measured GFR
Trial: NCT02318303
Drug: GSP 301-2 NS (BID)
RxNorm normalized name: NS-2
DrugBank: Reproxalap (DB16688)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSP 301-2 NS (665 μg olopatadine hydrochloride/25 μg mometasone furoate) administered as 2 sprays/nostril
Trial: NCT02318303
Drug: GSP 301 Placebo NS
RxNorm normalized name: NS-2
DrugBank: Reproxalap (DB16688)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSP 301 placebo NS administered as 2 sprays/nostril
Trial: NCT02318303
Drug: Olopatadine HCl-1 NS (QD)
RxNorm normalized name: NS-2
DrugBank: Olopatadine (DB00768)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Olopatadine HCl-1 NS (665 μg) administered as 2 sprays/nostril
Trial: NCT02318303
Drug: Olopatadine HCl-2 NS (BID)
RxNorm normalized name: NS-2
DrugBank: Olopatadine (DB00768)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Olopatadine HCl-2 NS (665 μg) administered as 2 sprays/nostril
Trial: NCT02318303
Drug: Mometasone Furoate-1 NS (QD)
RxNorm normalized name: mometasone furoate 1 MG/ML
DrugBank: Mometasone (DB00764)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mometasone furoate -1 NS (50 μg) administered as 2 sprays/nostril
Trial: NCT02318303
Drug: Mometasone Furoate-2 NS (BID)
RxNorm normalized name: mometasone furoate 2.2 MG/ML
DrugBank: Mometasone (DB00764)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mometasone furoate-2 NS (25 μg) administered as 2 sprays/nostril
Trial: NCT04150770
Drug: infliximab
RxNorm normalized name: Infliximab
DrugBank: Infliximab (DB00065)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT02993146
Drug: Ropidoxuridine
RxNorm normalized name: Ropidoxuridine
DrugBank: Ropidoxuridine (DB06485)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT00682357
Drug: Methylprednisolone and Lidocaine
RxNorm normalized name: lidocaine / methylprednisolone
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylprednisolone 80 mg, intra-articular and lidocaine 20 mg
Trial: NCT00682357
Drug: Methylprednisolone and Lidocaine
RxNorm normalized name: lidocaine / methylprednisolone
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylprednisolone 16 mg intra-articular and lidocaine 20 mg
Trial: NCT00682357
Drug: Placebo and Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Placebo and lidocaine 20 mg
Trial: NCT01902225
Drug: Istodax
RxNorm normalized name: Istodax
DrugBank: Romidepsin (DB06176)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01902225
Drug: Doxil
RxNorm normalized name: Doxil
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01171755
Drug: Gemcitabine TS-1
RxNorm normalized name: Ts-1 (TN)
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Gemcitabine (1,000mg/m2) will be administered on days 1 and 8 at every 3 weeks TS-1 will be administered orally according to body surface area (BSA) as follows : BSA\<1.25 M2, 80 mg/day; 1.25 M2≤BSA\<1.5 M2, 100 mg/day; 1.5 M2≤BSA, 120 mg/day for 14 consecutive days followed by a 7-day rest.
Trial: NCT00569855
Drug: Phenoxybenzamine
RxNorm normalized name: Phenoxybenzamine
DrugBank: Phenoxybenzamine (DB00925)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.125 to 1 mg/kg given i.v. over 15 to 45 minutes in preparation for cardiopulmonary bypass; may be continued at 0.125 mg/kg/day in ICU
Trial: NCT00437918
Drug: nateglinide
RxNorm normalized name: Nateglinide
DrugBank: Nateglinide (DB00731)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00437918
Drug: acarbose
RxNorm normalized name: Acarbose
DrugBank: Acarbose (DB00284)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03900754
Drug: Oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intranasal administration of oxytocin
Trial: NCT02098460
Drug: Atorvastatin, Probucol, Cilostazol
DrugBank: Atorvastatin (DB01076)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT06260072
Drug: magnesium and riboflavin supplement
RxNorm normalized name: Riboflavin
DrugBank: Riboflavin (DB00140)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Five capsules considered one dose of the intervention (one 400 mg magnesium capsule and four 100 mg riboflavin capsules)
Trial: NCT03778554
Drug: Metoprolol Succinate
RxNorm normalized name: Metoprolol Succinate
DrugBank: Metoprolol (DB00264)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Eligible patients randomized to receive long-term therapy with oral beta-blockade
Trial: NCT03778554
Drug: Bisoprolol
RxNorm normalized name: Bisoprolol
DrugBank: Bisoprolol (DB00612)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Eligible patients randomized to receive long-term therapy with oral beta-blockade
Trial: NCT03778554
Drug: Carvedilol
RxNorm normalized name: Carvedilol
DrugBank: Carvedilol (DB01136)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Eligible patients randomized to receive long-term therapy with oral beta-blockade
Trial: NCT03778554
Drug: Nebivolol
RxNorm normalized name: Nebivolol
DrugBank: Nebivolol (DB04861)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Eligible patients randomized to receive long-term therapy with oral beta-blockade
Trial: NCT02248883
Drug: TPV low
RxNorm normalized name: low-density polyethylene
DrugBank: Poly(lactic acid) (DB15037)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02248883
Drug: Moxifloxacin
RxNorm normalized name: Moxifloxacin
DrugBank: Moxifloxacin (DB00218)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02248883
Drug: TPV high
RxNorm normalized name: high-density polyethylene
DrugBank: Poly(lactic acid) (DB15037)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01960023
Drug: Cetuximab
RxNorm normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 400 mg/m2 IV loading dose followed by weekly cetuximab 250 mg/m2 IV until disease progression
Trial: NCT01960023
Drug: Neratinib
RxNorm normalized name: NERATINIB
DrugBank: Neratinib (DB11828)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Phase I portion of the study:~Dose level 1: 120 mg/day; Dose level 2: 160 mg/day; Dose level 3: 200 mg/day; Dose level 4: 240 mg/day~Phase II portion of the study: The recommended dose determined in the Phase I portion of the study.
Trial: NCT04639219
Drug: Trastuzumab deruxtecan
RxNorm normalized name: Trastuzumab deruxtecan
DrugBank: Trastuzumab deruxtecan (DB14962)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Trastuzumab deruxtecan (T-DXd) by intravenous infusion
Trial: NCT01314937
Drug: Mebendazole
RxNorm normalized name: Mebendazole
DrugBank: Mebendazole (DB00643)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single-dose 500 mg mebendazole tablet
Trial: NCT04172597
Drug: Poziotinib Hydrochloride
RxNorm normalized name: Chlorpromazine Hydrochloride
DrugBank: Poziotinib (DB12114)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The poziotinib drug substance is a hydrochloride salt of poziotinib and is formulated as a tablet for oral administration.
Trial: NCT04172597
Drug: Loperamide
RxNorm normalized name: Loperamide
DrugBank: Loperamide (DB00836)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Loperamide as prescribed by the physician.
Trial: NCT03420586
Drug: Nitrous Oxide
RxNorm normalized name: Nitrous Oxide
DrugBank: Nitrous oxide (DB06690)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The nitrous oxide group (GN2O) will receive 70% N2O in 30% O2 at the end of surgery.
Trial: NCT01881984
Drug: Ravicti
RxNorm normalized name: Ravicti
DrugBank: Glycerol phenylbutyrate (DB08909)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Open-label design comparing Ravicti at doses of 2, 4, and 6 grams/m2/day
Trial: NCT00469664
Drug: Guanfacine/Tenex
DrugBank: Guanfacine (DB01018)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT04582084
Drug: Etanercept
RxNorm normalized name: Etanercept
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Patients received biosimilar etanercept 25 mg twice weekly or 50 mg once weekly.
Trial: NCT00157924
Drug: atorvastatin
RxNorm normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: atorvastatin 10mg
Trial: NCT00034736
Drug: Levofloxacin
RxNorm normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02695810
Drug: Dapagliflozin
RxNorm normalized name: Dapagliflozin
DrugBank: Dapagliflozin (DB06292)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 10 mg per day as monotherapy for 13 weeks
Trial: NCT02695810
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 2 x 850 mg per day as monotherapy for 13 weeks
Trial: NCT00055042
Drug: Vitamin E
RxNorm normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03852537
Drug: Methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylprednisolone will be administered based on CRP-guided protocol outlined under 'Biomarker-adjusted steroid dosing'.
Trial: NCT00233402
Drug: Hexvix
DrugBank: Hexaminolevulinate (DB06261)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single Instillation, Transurethral Resection of the Bladder
Trial: NCT00074828
Drug: enoxaparin
RxNorm normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03276078
Drug: Aclidinium Bromide/Formoterol Fumarate 400/12μg BID
DrugBank: Clidinium (DB00771)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aclidinium bromide/formoterol fumarate 400/12μg administered by inhalation via the Genuair® multidose dry powder inhaler, twice daily (morning and evening) for 5 days
Trial: NCT00206323
Drug: Topiramate (drug)
RxNorm normalized name: Topiramate
DrugBank: Topiramate (DB00273)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Topiramate 25 mg titrated to 200 mg
Trial: NCT03477903
Drug: TAK-954
RxNorm normalized name: TAK-243
DrugBank: TAK-243 (DB15013)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-954 infusion
Trial: NCT03477903
Drug: Metoclopramide
RxNorm normalized name: Metoclopramide
DrugBank: Metoclopramide (DB01233)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Metoclopramide infusion
Trial: NCT00927732
Drug: hydroquinidine
RxNorm normalized name: Hydroquinidine
DrugBank: Hydroquinidine (DB15300)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: capsules of 300 mg LP, 1 or 2 or 3 times per day : frequency will be determined by tests after patient inclusion before her/his randomization
Trial: NCT01147107
Drug: Raltegravir
RxNorm normalized name: Raltegravir
DrugBank: Raltegravir (DB06817)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Emtricitabine/tenofovir DF\* 200 mg/300 mg po daily + Raltegravir 400 mg twice daily
Trial: NCT01147107
Drug: Efavirenz
RxNorm normalized name: Efavirenz
DrugBank: Efavirenz (DB00625)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Emtricitabine/tenofovir DF\* 200 mg/300 mg po daily + Efavirenz 600 mg po daily
Trial: NCT00482807
Drug: bicalutamide
RxNorm normalized name: Bicalutamide
DrugBank: Bicalutamide (DB01128)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00482807
Drug: docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00482807
Drug: goserelin
RxNorm normalized name: Goserelin
DrugBank: Goserelin (DB00014)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03357653
Drug: Losartan group
DrugBank: Losartan (DB00678)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Losartan 50 mg daily
Trial: NCT02686138
Drug: Tenapanor
RxNorm normalized name: Tenapanor
DrugBank: Tenapanor (DB11761)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01819610
Drug: SPRIX
RxNorm normalized name: Sprix
DrugBank: Ketorolac (DB00465)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02379572
Drug: 5-ALA-guided surgery
RxNorm normalized name: 5-ALA
DrugBank: Aminolevulinic acid (DB00855)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: For 5-ALA guided glioma resections patients have to drink 100ml of a solution with 5-Aminolevulinic acid 4-6 hours before surgery. Intraoperatively the light source of the surgical microscope can be switched to a certain wave length to enable fluorescence of the glioma cells, which helps resecting the tumor as radical as possible.
Trial: NCT00270907
Drug: CT-2103
RxNorm normalized name: CT-179
DrugBank: CT-179 (DB17114)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 135 mg/m\^2 IV on Day 1.
Trial: NCT00270907
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1000 mg/m\^2 IV on Day 1 and 8.
Trial: NCT03886415
Drug: Jaktinib hydrochloride tablets
RxNorm normalized name: sevelamer hydrochloride Oral Tablet
DrugBank: Jaktinib (DB17545)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Jaktinib hydrochloride tablets 100mg bid dose group and Jaktinib hydrochloride tablets 200mg qd dose group
Trial: NCT01953978
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous administration of dexamethasone 16 mg (concentration 4 mg/ml, volume 4 ml) immediately after endotracheal intubation
Trial: NCT01953978
Drug: Morphine
RxNorm normalized name: Morphine
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Morphine. Patient controlled intravenous morphine (PCA-pump), bolus 2.5 mg, lock-out-time 10 minutes. Concentration : Morphin 1 mg/ml.
Trial: NCT01953978
Drug: Zofran
RxNorm normalized name: Zofran
DrugBank: Ondansetron (DB00904)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Zofran 4 mg iv in case of moderate to severe nausea, supplemented by Zofran 1 mg iv if needed
Trial: NCT01953978
Drug: Paracetamol
RxNorm normalized name: Paracetamol
DrugBank: Acetaminophen (DB00316)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tablet Paracetamol 1 g orally, 1 hour preoperatively and every 6 hours after extubation time during the first 48 hours.
Trial: NCT01449370
Drug: TAK-117
RxNorm normalized name: TAK-243
DrugBank: TAK-243 (DB15013)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral administration of TAK-117, daily and intermittent schedules.
Trial: NCT00387556
Drug: Ondansetron
RxNorm normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ondansetron (0.15 mg/kg/dose; maximum dose 4 mg)
Trial: NCT00229177
Drug: ONO-2506
RxNorm normalized name: ONO-2952
DrugBank: ONO-2952 (DB14802)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily one-hour intravenous infusion at 12/mg/kg/hr for 7 days
Trial: NCT00229177
Drug: ONO-2506
RxNorm normalized name: ONO-2952
DrugBank: ONO-2952 (DB14802)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily one-hour intravenous infusion at 0 mg/kg/hr for 7 days
Trial: NCT00229177
Drug: ONO-2506
RxNorm normalized name: ONO-2952
DrugBank: ONO-2952 (DB14802)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily one-hour intravenous infusion at 8 mg/kg/hr for 7 days
Trial: NCT01900951
Drug: Temozolomide
RxNorm normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01406444
Drug: rhIGF-1
RxNorm normalized name: rhIGF-I/rhIGFBP-3
DrugBank: Mecasermin rinfabate (DB14751)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Study participants will be started at a dose of 30 mcg/kg BID and will be titrated.
Trial: NCT01406444
Drug: Risedronate
RxNorm normalized name: Risedronate
DrugBank: Risedronic acid (DB00884)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Risedronate 35mg PO one time weekly
Trial: NCT01814553
Drug: afatinib
RxNorm normalized name: Afatinib
DrugBank: Afatinib (DB08916)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Daily treatment starting 40 mg per day
Trial: NCT01814553
Drug: loperamide
RxNorm normalized name: Loperamide
DrugBank: Loperamide (DB00836)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Follow cohort assignment and diarrhea management guidelines
Trial: NCT00673049
Drug: Erlotinib
RxNorm normalized name: Erlotinib
DrugBank: Erlotinib (DB00530)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Erlotinib (one tablet of 150 mg/day PO).
Trial: NCT00376038
Drug: metformin tablets
RxNorm normalized name: metformin Oral Tablet
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT03616717
Drug: Modafinil
RxNorm normalized name: Modafinil
DrugBank: Modafinil (DB00745)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Drug: modafinil Each participant receives a single pill of placebo or active drug (modafinil 100 mg or 200 mg) 30 minutes after arriving at the lab. The participant then completes approximately 6 hours of testing in the laboratory. The participant stays at the lab for 7.5 hours in order to monitor physical condition in case the participant received the active pill. One week later, that participant receives a single pill of an alternate comparator and is again tested in the laboratory. Thus, in total, each participant receives one placebo pill and two active pills, each time separated by one week.~Other Names:~Provigil Alertec Modavigil
Trial: NCT00967655
Drug: irinotecan hydrochloride
RxNorm normalized name: Irinotecan Hydrochloride
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00562523
Drug: Sorafenib (Nexavar, BAY43-9006)
RxNorm normalized name: sorafenib 200 MG [Nexavar]
DrugBank: Sorafenib (DB00398)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sorafenib 400mg by mouth daily in combination with docetaxel 60mg/m2 IV once every 3 weeks
Trial: NCT01254383
Drug: Sildenafil Tablet
RxNorm normalized name: Sildenafil Tablets
DrugBank: Sildenafil (DB00203)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tablet, 50 mg, Single Dose
Trial: NCT01254383
Drug: Sildenafil ODT
DrugBank: Sildenafil (DB00203)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Orally Disintegrating Tablet, 50 mg, Single Dose
Trial: NCT00217555
Drug: gemcitabine hydrochloride
RxNorm normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00217555
Drug: topotecan hydrochloride
RxNorm normalized name: Topotecan Hydrochloride
DrugBank: Topotecan (DB01030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04290195
Drug: Ziv-Aflibercept 25 MG/ML [Zaltrap]
RxNorm normalized name: ziv-aflibercept 25 MG/ML [Zaltrap]
DrugBank: Aflibercept (DB08885)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravitreal injection of 1.25 mg of ziv aflibercept in patients
Trial: NCT01739660
Drug: Pegloticase
RxNorm normalized name: Pegloticase
DrugBank: Pegloticase (DB09208)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: a single 8 mg iv (in the vein) dose before hemodialysis session
Trial: NCT01589497
Drug: Rifampicin
RxNorm normalized name: Rifampicin
DrugBank: Rifampin (DB01045)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants with body weight \</= 50kg were administered one 450 mg tablet orally once daily. Participants with body weight \>50kg were administered one 600 mg tablet orally once daily.
Trial: NCT01589497
Drug: Isoniazid
RxNorm normalized name: Isoniazid
DrugBank: Isoniazid (DB00951)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants were administered three 100 mg tablets or one 300 mg tablet once daily.
Trial: NCT01589497
Drug: Pyrazinamide
RxNorm normalized name: Pyrazinamide
DrugBank: Pyrazinamide (DB00339)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants with a body weight of 40-55 kg were administered two 500 mg tablets orally once daily. Participants with a body weight of 56-75 kg were administered three 500 mg tablets orally once daily. Participants with a body weight of 76-90 kg were administered four 500 mg tablets orally once daily.
Trial: NCT01589497
Drug: Ethambutol
RxNorm normalized name: Ethambutol
DrugBank: Ethambutol (DB00330)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants with a body weight of 40-55 kg were administered two 400 mg tablets orally once daily. Participants with a body weight of 56-75 kg were administered three 400 mg tablets orally once daily. Participants with a body weight of 76-90 kg were administered four 400 mg tablets orally once daily.
Trial: NCT01589497
Drug: Moxifloxacin
RxNorm normalized name: Moxifloxacin
DrugBank: Moxifloxacin (DB00218)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants were administered one 400 mg tablet orally once a day.
Trial: NCT03390426
Drug: Mepivacaine
RxNorm normalized name: Mepivacaine
DrugBank: Mepivacaine (DB00961)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: An ultrasound guided injection of mepivacaine superomedially to the femoral artery.
Trial: NCT03390426
Drug: Saline
RxNorm normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: An ultrasound guided injection using a medication that does NOT numb any nerves called saline, or salt water.